Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Spriggs

Showing results (41-50 of 68) with videos related to

Pageof 7
Sort By:
Cancer|October 16, 2013
Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm studyWilliam P Tew, Nicoletta Colombo, Isabelle Ray-Coquard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2002
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignanciesCarol Aghajanian, Steven Soignet, Don S Dizon, et al.
Cancers|April 26, 2016
A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First RemissionRoisin E O'Cearbhaill, Govind Ragupathi, Jianglong Zhu, et al.
Gynecologic Oncology|May 15, 2012
Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinomaDavid M Hyman, Kara C Long, Edward J Tanner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remissionCatherine S M Diefenbach, Sacha Gnjatic, Paul Sabbatini, et al.
Molecular Cancer Therapeutics|April 12, 2022
Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective AgentsThapi D Rao, Mengyao Xu, Stephanie Eng, et al.
Cancer|August 30, 2012
BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancerRachel N Grisham, Gopa Iyer, Karuna Garg, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 25, 2010
Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomasXingxing Zang, Peggy S Sullivan, Robert A Soslow, et al.
Cancer|December 6, 2011
Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancerDavid M Hyman, Qin Zhou, Alexia Iasonos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2011
Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancerJason A Konner, Diana M Grabon, Scott R Gerst, et al.
Pageof 7

Showing results (41-50 of 68) with videos related to

Sort By:
Pageof 7
Cancer|October 16, 2013
Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm studyWilliam P Tew, Nicoletta Colombo, Isabelle Ray-Coquard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2002
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignanciesCarol Aghajanian, Steven Soignet, Don S Dizon, et al.
Cancers|April 26, 2016
A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First RemissionRoisin E O'Cearbhaill, Govind Ragupathi, Jianglong Zhu, et al.
Gynecologic Oncology|May 15, 2012
Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinomaDavid M Hyman, Kara C Long, Edward J Tanner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remissionCatherine S M Diefenbach, Sacha Gnjatic, Paul Sabbatini, et al.
Molecular Cancer Therapeutics|April 12, 2022
Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective AgentsThapi D Rao, Mengyao Xu, Stephanie Eng, et al.
Cancer|August 30, 2012
BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancerRachel N Grisham, Gopa Iyer, Karuna Garg, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 25, 2010
Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomasXingxing Zang, Peggy S Sullivan, Robert A Soslow, et al.
Cancer|December 6, 2011
Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancerDavid M Hyman, Qin Zhou, Alexia Iasonos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2011
Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancerJason A Konner, Diana M Grabon, Scott R Gerst, et al.
Pageof 7